NCT05605509 2026-02-06
RP-6306 in Patients With Advanced Cancer
Canadian Cancer Trials Group
Phase 2 Completed
Canadian Cancer Trials Group
Suzhou Transcenta Therapeutics Co., Ltd.
M.D. Anderson Cancer Center
Eli Lilly and Company
M.D. Anderson Cancer Center